On June 29th, the 9th China BioMed Innovation and Cooperation Conference and the 2023 China BioMed Industry Value List Awards Ceremony officially opened in Suzhou. The list of winners was announced at the event, and Hopstem's strength in the field of biotechnology was once again recognized by the industry, ranking in the top 10 most promising biotech companies.
This ranking reflects the industry's high recognition of Hopstem's innovative iPSC-derived cell therapy platform. In the future, we will continue to adhere to the concept of "Unlimited Innovation to change life", continuously develop and promote the company's clinical pipeline, and benefit patients as soon as possible.
Hopstem hNPC01 Earns FDA RMAT Designation for Chronic Stroke Therapy
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
Hopstem Announces FDA Granted iPSC Therapy hNPC01 Injection Fast Track Designation, Accelerating Global Breakthrough in Treatment of Cerebral Neural Injury Diseases
Hopstem Won First Place at 2024 SAPA Investment Forum & online Road Show with Innovative iPSC Cell Therapy for Chronic Stroke
R&D Center: Building 11,Heda Medicine Valley V, Qiantang Area,
Hangzhou, Zhejiang, China
Manufacturing Center: 3rd & 4th Floor, Building 10,Heda Medicine Valley lll,
Qiantang Area, Hangzhou, Zhejiang, China
U.S. Office: 103 Carnegie center, Suite 300, Princeton,
NJ 08540, USA
